NSG 552 Exam 4 V1 | NSG 552
Psychopharmacology | Wilkes University |
2026 Q&A with Rationale (Wilkes NSG552
Exam 4 2026)
1. A 9-year-old male is diagnosed with ADHD, predominantly inattentive type. Which of the
following best describes the mechanism of action of Methylphenidate in treating this
condition?
A. It stimulates the direct release of serotonin from the presynaptic vesicles.
B. It acts primarily by blocking the reuptake of norepinephrine and dopamine via
transporter inhibition.
C. It acts as a potent agonist at the post-synaptic alpha-2 adrenergic receptors.
D. It inhibits the monoamine oxidase enzyme system to increase synaptic concentrations of
GABA.
Answer: B
Rationale: Methylphenidate functions by inhibiting the reuptake of dopamine and
norepinephrine, thereby increasing their availability in the synaptic cleft. This mechanism
helps to enhance focus and reduce impulsivity in patients with ADHD. Unlike
amphetamines, it does not primarily promote the efflux or release of these
neurotransmitters from storage vesicles.
,2. When prescribing Atomoxetine for a pediatric patient, which black box warning must the
PMHNP discuss with the family?
A. Increased risk of suicidal ideation in children and adolescents.
B. Potential for severe hypertensive crisis when combined with tyramine.
C. High risk of hepatotoxicity leading to acute liver failure within 48 hours.
D. Risk of Stevens-Johnson Syndrome requiring immediate cessation of the drug.
Answer: A
Rationale: Atomoxetine carries a black box warning regarding the increased risk of
suicidal ideation in pediatric populations. It is essential for clinicians to monitor patients
closely for changes in behavior or mood during the initial months of therapy. Families
should be educated on recognizing signs of emotional lability or withdrawal.
3. A patient seeking treatment for Alcohol Use Disorder is prescribed Acamprosate. What is
the primary mechanism by which this medication supports abstinence?
A. Modulating glutamate and GABA neurotransmission to restore balance after chronic
alcohol use.
B. Blocking opioid receptors to reduce the rewarding effects of drinking.
C. Inducing a severe physical reaction when alcohol is consumed.
D. Increasing the half-life of ethanol to maintain a steady state of mild intoxication.
Answer: A
,Rationale: Acamprosate is thought to interact with the NMDA glutamate receptors and
GABA receptors to reduce the post-withdrawal hyperexcitability. This helps alleviate the
negative reinforcement associated with alcohol withdrawal symptoms. It is most effective
when initiated after the patient has achieved abstinence.
4. Which pharmacological profile describes Buprenorphine’s action at the mu-opioid
receptor?
A. Full agonist with high affinity and high intrinsic activity.
B. Partial agonist with high affinity and low intrinsic activity.
C. Competitive antagonist with low affinity and no intrinsic activity.
D. Inverse agonist that reduces baseline receptor signaling.
Answer: B
Rationale: Buprenorphine is a partial mu-opioid agonist, meaning it binds strongly to the
receptor but produces a sub-maximal response. This ‘ceiling effect’ reduces the risk of
respiratory depression compared to full agonists like methadone. Its high affinity also
allows it to displace other opioids, which can precipitate withdrawal if not managed
correctly.
5. In the treatment of Alzheimer’s Disease, Memantine works through which of the following
mechanisms?
A. Increasing acetylcholine levels by inhibiting acetylcholinesterase.
B. Stimulating the production of amyloid-beta plaques to stabilize neurons.
, C. Acting as an uncompetitive antagonist at NMDA glutamate receptors.
D. Blocking dopamine D2 receptors in the prefrontal cortex.
Answer: C
Rationale: Memantine regulates glutamate activity by acting as an NMDA receptor
antagonist, which prevents excessive calcium influx that leads to neurotoxicity. By reducing
‘background noise’ from pathological glutamate levels, it allows for better signal detection.
This medication is often used in moderate to severe stages of Alzheimer’s disease.
6. A PMHNP is considering Guanfacine ER for a child with ADHD and comorbid tics. Why is
this choice appropriate?
A. Guanfacine is a stimulant that does not cross the blood-brain barrier.
B. It works by increasing the turnover of serotonin in the motor cortex.
C. It provides rapid-onset sedation which masks the physical symptoms of tics.
D. It is an alpha-2A adrenergic agonist that can reduce tics and improve executive function.
Answer: D
Rationale: Guanfacine ER is a selective alpha-2A adrenergic agonist that strengthens the
signal in the prefrontal cortex. It is often preferred over stimulants when tics are present
because stimulants can sometimes exacerbate motor or vocal tics. This medication helps
improve symptoms of hyperactivity and impulsivity effectively.
Psychopharmacology | Wilkes University |
2026 Q&A with Rationale (Wilkes NSG552
Exam 4 2026)
1. A 9-year-old male is diagnosed with ADHD, predominantly inattentive type. Which of the
following best describes the mechanism of action of Methylphenidate in treating this
condition?
A. It stimulates the direct release of serotonin from the presynaptic vesicles.
B. It acts primarily by blocking the reuptake of norepinephrine and dopamine via
transporter inhibition.
C. It acts as a potent agonist at the post-synaptic alpha-2 adrenergic receptors.
D. It inhibits the monoamine oxidase enzyme system to increase synaptic concentrations of
GABA.
Answer: B
Rationale: Methylphenidate functions by inhibiting the reuptake of dopamine and
norepinephrine, thereby increasing their availability in the synaptic cleft. This mechanism
helps to enhance focus and reduce impulsivity in patients with ADHD. Unlike
amphetamines, it does not primarily promote the efflux or release of these
neurotransmitters from storage vesicles.
,2. When prescribing Atomoxetine for a pediatric patient, which black box warning must the
PMHNP discuss with the family?
A. Increased risk of suicidal ideation in children and adolescents.
B. Potential for severe hypertensive crisis when combined with tyramine.
C. High risk of hepatotoxicity leading to acute liver failure within 48 hours.
D. Risk of Stevens-Johnson Syndrome requiring immediate cessation of the drug.
Answer: A
Rationale: Atomoxetine carries a black box warning regarding the increased risk of
suicidal ideation in pediatric populations. It is essential for clinicians to monitor patients
closely for changes in behavior or mood during the initial months of therapy. Families
should be educated on recognizing signs of emotional lability or withdrawal.
3. A patient seeking treatment for Alcohol Use Disorder is prescribed Acamprosate. What is
the primary mechanism by which this medication supports abstinence?
A. Modulating glutamate and GABA neurotransmission to restore balance after chronic
alcohol use.
B. Blocking opioid receptors to reduce the rewarding effects of drinking.
C. Inducing a severe physical reaction when alcohol is consumed.
D. Increasing the half-life of ethanol to maintain a steady state of mild intoxication.
Answer: A
,Rationale: Acamprosate is thought to interact with the NMDA glutamate receptors and
GABA receptors to reduce the post-withdrawal hyperexcitability. This helps alleviate the
negative reinforcement associated with alcohol withdrawal symptoms. It is most effective
when initiated after the patient has achieved abstinence.
4. Which pharmacological profile describes Buprenorphine’s action at the mu-opioid
receptor?
A. Full agonist with high affinity and high intrinsic activity.
B. Partial agonist with high affinity and low intrinsic activity.
C. Competitive antagonist with low affinity and no intrinsic activity.
D. Inverse agonist that reduces baseline receptor signaling.
Answer: B
Rationale: Buprenorphine is a partial mu-opioid agonist, meaning it binds strongly to the
receptor but produces a sub-maximal response. This ‘ceiling effect’ reduces the risk of
respiratory depression compared to full agonists like methadone. Its high affinity also
allows it to displace other opioids, which can precipitate withdrawal if not managed
correctly.
5. In the treatment of Alzheimer’s Disease, Memantine works through which of the following
mechanisms?
A. Increasing acetylcholine levels by inhibiting acetylcholinesterase.
B. Stimulating the production of amyloid-beta plaques to stabilize neurons.
, C. Acting as an uncompetitive antagonist at NMDA glutamate receptors.
D. Blocking dopamine D2 receptors in the prefrontal cortex.
Answer: C
Rationale: Memantine regulates glutamate activity by acting as an NMDA receptor
antagonist, which prevents excessive calcium influx that leads to neurotoxicity. By reducing
‘background noise’ from pathological glutamate levels, it allows for better signal detection.
This medication is often used in moderate to severe stages of Alzheimer’s disease.
6. A PMHNP is considering Guanfacine ER for a child with ADHD and comorbid tics. Why is
this choice appropriate?
A. Guanfacine is a stimulant that does not cross the blood-brain barrier.
B. It works by increasing the turnover of serotonin in the motor cortex.
C. It provides rapid-onset sedation which masks the physical symptoms of tics.
D. It is an alpha-2A adrenergic agonist that can reduce tics and improve executive function.
Answer: D
Rationale: Guanfacine ER is a selective alpha-2A adrenergic agonist that strengthens the
signal in the prefrontal cortex. It is often preferred over stimulants when tics are present
because stimulants can sometimes exacerbate motor or vocal tics. This medication helps
improve symptoms of hyperactivity and impulsivity effectively.
